Advances in immunotherapy for biliary tract cancers

被引：0
作者：
Zhao Yuhao [1 ,2 ,3 ,4 ]
Yang Mao [1 ,2 ,3 ,4 ]
Feng Jiayi [1 ,2 ,3 ,4 ]
Wang Xuan [1 ,2 ,3 ,4 ]
Liu Yingbin [1 ,2 ,3 ,4 ]
机构：
[1] Department of Biliary-Pancreatic Surgery
[2] Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
[3] Shanghai
[4] China
来源：
中华医学杂志英文版 | 2024年 / 137卷 / 05期
关键词：
Immunotherapy; Biliary tract cancers; Immune checkpoint inhibitors; Cholangiocarcinoma; Gallbladder cancer;
D O I：
暂无
中图分类号：
R735.8 [胆囊、胆道肿瘤];
学科分类号：
100214 ;
摘要：
Biliary tract cancers (BTC), a heterogeneous disease with poor prognosis, including gallbladder cancer (GBC), intrahepatic cholangiocarcinoma (ICC), and extrahepatic cholangiocarcinoma (ECC). Although surgery is currently the primary regimen to treat BTC, most BTC patients are diagnosed at an advanced stage and miss the opportunity of surgical eradication. As a result, non-surgical therapy serves as the main intervention for advanced BTC. In recent years, immunotherapy has emerged as one of the most promising therapies in a number of solid cancers, and it includes immune checkpoint inhibitors (ICIs) monotherapy or combined therapy, tumor vaccines, oncolytic virus immunotherapy, adoptive cell therapy (ACT), and cytokine therapy. However, these therapies have been practiced in limited clinical settings in patients with BTC. In this review, we focus on the discussion of latest advances of immunotherapy in BTC and update the progress of multiple current clinical trials with different immunotherapies.
引用
收藏
相关论文
共 79 条
[1]   Novel protein kinase inhibitor TT-00420 inhibits gallbladder cancer by inhibiting JNK/JUN-mediated signaling pathway [J].
Miao, Huijie ;
Geng, Yajun ;
Li, Yang ;
Tang, Shijie ;
Feng, Feiling ;
Li, Weijian ;
Li, Yongsheng ;
Liu, Liguo ;
Zhang, Rui ;
Qiu, Shimei ;
Wu, Ying ;
Wang, Zeyu ;
Wang, Ziyi ;
Shao, Ziyu ;
Liu, Ke ;
Zou, Lu ;
Yang, Mao ;
Zhao, Yuhao ;
Chen, Chen ;
Li, Zhizhen ;
Zhang, Dadong ;
Peng, Peng ;
Qiang, Xiaoyan ;
Wu, Frank ;
He, Yongning ;
Chen, Luonan ;
Xiang, Dongxi ;
Jiang, Xiaoqing ;
Li, Maolan ;
Liu, Yun ;
Liu, Yingbin .
CELLULAR ONCOLOGY, 2022, 45 (04) :689-708
[2]   IFNa Potentiates Anti-PD-1 Efficacy by Remodeling Glucose Metabolism in the Hepatocellular Carcinoma Microenvironment [J].
Hu, Bo ;
Yu, Mincheng ;
Ma, Xiaolu ;
Sun, Jialei ;
Liu, Chenglong ;
Wang, Chunyan ;
Wu, Suiyi ;
Fu, Peiyao ;
Yang, Zhen ;
He, Yungang ;
Zhu, Yuanyuan ;
Huang, Cheng ;
Yang, Xinrong ;
Shi, Yinghong ;
Qiu, Shuangjian ;
Sun, Huichuan ;
Zhu, Andrew X. ;
Zhou, Jian ;
Xu, Yang ;
Zhu, Di ;
Fan, Jia .
CANCER DISCOVERY, 2022, 12 (07) :1718-1741
[3]   Hepatobiliary Tumor Organoids Reveal HLA Class I Neoantigen Landscape and Antitumoral Activity of Neoantigen Peptide Enhanced with Immune Checkpoint Inhibitors [J].
Wang, Wenwen ;
Yuan, Tinggan ;
Ma, Lili ;
Zhu, Yanjing ;
Bao, Jinxia ;
Zhao, Xiaofang ;
Zhao, Yan ;
Zong, Yali ;
Zhang, Yani ;
Yang, Shuai ;
Qiu, Xinyao ;
Shen, Siyun ;
Wu, Rui ;
Wu, Tong ;
Wang, Hongyang ;
Gao, Dong ;
Wang, Peng ;
Chen, Lei .
ADVANCED SCIENCE, 2022, 9 (22)
[4]   Mapping the developing human immune system across organs [J].
Suo, Chenqu ;
Dann, Emma ;
Goh, Issac ;
Jardine, Laura ;
Kleshchevnikov, Vitalii ;
Park, Jong-Eun ;
Botting, Rachel A. ;
Stephenson, Emily ;
Engelbert, Justin ;
Tuong, Zewen Kelvin ;
Polanski, Krzysztof ;
Yayon, Nadav ;
Xu, Chuan ;
Suchanek, Ondrej ;
Elmentaite, Rasa ;
Conde, Cecilia Dominguez ;
He, Peng ;
Pritchard, Sophie ;
Miah, Mohi ;
Moldovan, Corina ;
Steemers, Alexander S. ;
Mazin, Pavel ;
Prete, Martin ;
Horsfall, Dave ;
Marioni, John C. ;
Clatworthy, Menna R. ;
Haniffa, Muzlifah ;
Teichmann, Sarah A. .
SCIENCE, 2022, 376 (6597) :1069-+
[5]   The role of tumor-infiltrating lymphocytes in cholangiocarcinoma [J].
Liu, Dong ;
Heij, Lara Rosaline ;
Czigany, Zoltan ;
Dahl, Edgar ;
Lang, Sven Arke ;
Ulmer, Tom Florian ;
Luedde, Tom ;
Neumann, Ulf Peter ;
Bednarsch, Jan .
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2022, 41 (01)
[6]   Evolving Role of Immunotherapy in Advanced Biliary Tract Cancers [J].
Kang, Sandra ;
El-Rayes, Bassel F. ;
Akce, Mehmet .
CANCERS, 2022, 14 (07)
[7]   Recent Advances and Next Breakthrough in Immunotherapy for Cancer Treatment [J].
Yang, Ling ;
Ning, Qian ;
Tang, Sheng-song .
JOURNAL OF IMMUNOLOGY RESEARCH, 2022, 2022
[8]   Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics [J].
Yamaguchi, Hirohito ;
Hsu, Jung-Mao ;
Yang, Wen-Hao ;
Hung, Mien-Chie .
NATURE REVIEWS CLINICAL ONCOLOGY, 2022, 19 (05) :287-305
[9]   Pembrolizumab (PEM) plus granulocyte macrophage colony stimulating factor (GM-CSF) in advanced biliary cancers (ABC): Final outcomes of a phase 2 trial [J].
Kelley, Robin Kate ;
Bracci, Paige M. ;
Keenan, Bridget ;
Behr, Spencer ;
Ibrahim, Faaiz ;
Pollak, Marin ;
Gordan, John ;
Ko, Andrew H. ;
Van Loon, Katherine ;
Atreya, Chloe Evelyn ;
Cinar, Pelin ;
Venook, Alan P. ;
Fong, Lawrence .
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
[10]   Multicenter randomized phase II trial of atezolizumab with or without cobimetinib in biliary tract cancers [J].
Yarchoan, Mark ;
Cope, Leslie ;
Ruggieri, Amanda N. ;
Anders, Robert A. ;
Noonan, Anne M. ;
Goff, Laura W. ;
Goyal, Lipika ;
Lacy, Jill ;
Li, Daneng ;
Patel, Anuj K. ;
He, Aiwu R. ;
Abou-Alfa, Ghassan K. ;
Spencer, Kristen ;
Kim, Edward J. ;
Davis, S. Lindsey ;
McRee, Autumn J. ;
Kunk, Paul R. ;
Goyal, Subir ;
Liu, Yuan ;
Dennison, Lauren ;
Xavier, Stephanie ;
Mohan, Aditya A. ;
Zhu, Qingfeng ;
Wang-Gillam, Andrea ;
Poklepovic, Andrew ;
Chen, Helen X. ;
Sharon, Elad ;
Lesinski, Gregory B. ;
Azad, Nilofer S. .
JOURNAL OF CLINICAL INVESTIGATION, 2021, 131 (24)
12345678